Shire Scraps Development of Vyvanse for Depression

Drug Industry Daily
A A
Shire said Thursday it will abandon the development of its blockbuster hyperactivity drug Vyvanse as a treatment for major depressive disorder after two failed Phase III trials.

To View This Article:

Login

Subscribe To Drug Industry Daily